A Phase I Study of Safety and Tolerability of Single-dose Human Umbilical Cord Mesenchymal Stem Cell (IxCell hUC-MSC-S) in Patients With Convalescent Phase of Ischemic Stroke
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy Shanghai IxCell Biotechnology (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Shanghai IxCell Biotechnology
- 03 Dec 2024 Status changed to completed.
- 10 Apr 2023 Planned initiation date changed from 1 Mar 2023 to 15 Apr 2023.
- 03 Feb 2023 New trial record